ML19177A305

From kanterella
Revision as of 16:31, 19 October 2019 by StriderTol (talk | contribs) (Created page by program invented by StriderTol)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Shine Medical Technologies. Inc. Notification of Closing Date for Indirect Transfer of the Shine Medical Isotope Production Facility Construction Permit
ML19177A305
Person / Time
Site: SHINE Medical Technologies
Issue date: 06/26/2019
From: Jim Costedio
SHINE Medical Technologies
To:
Document Control Desk, Office of Nuclear Reactor Regulation
References
2019-SMT-0050
Download: ML19177A305 (1)


Text

June 26, 2019 2019-SMT-0050 10 CFR 50.80 10 CFR 50.90 U.S. Nuclear Regulatory Commission ATTN: Document Control Desk Director, Office of Nuclear Reactor Regulation Washington, DC 20555

References:

(1) U.S. Nuclear Regulatory Commission, Order Approving the Indirect Transfer of License and Conforming Amendment, dated May 20, 2019, (ML19102A324)

SHINE Medical Technologies. Inc. Notification of Closing Date for Indirect Transfer of the SHINE Medical Isotope Production Facility Construction Permit In accordance with Section Ill of the Order Approving the Indirect Transfer of License and Conforming Amendment (Reference 1), SHINE is providing the required notification to the Director of the Office of Nuclear Reactor Regulation. The date of closing of the indirect transfer described in Reference (1) will be July 1, 2019.

If you have any questions, please contact Mr. Jeff Bartelme, Director of Licensing, at 608/210-1735.

Very truly yours, Jtt!!?

Vice President of Regulatory Affairs and Quality SHINE Medical Technologies, Inc.

Docket No. 50-608 cc: Project Manager, USNRC Supervisor, Radioactive Materials Program, Wisconsin Division of Public Health 101 E. Milwaukee Street, Suite 600 I Janesville, WI 53545 I P (608) 210-1060 I F (608) 210-2504 I www.shinemed.com